查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2052144

原代肝細胞市場：市場洞察、競爭格局及市場預測（2033 年）

Primary Hepatocytes Market Insights, Competitive Landscape, and Market Forecast - 2033
出版日期: | 出版商: Fairfield Market Research | 英文 184 Pages | 商品交期: 2-5個工作天內

價格
簡介目錄

由於藥物研發、毒性測試和肝病研究領域對先進的細胞模型的需求不斷成長，原代肝細胞市場正經歷顯著成長。原代肝細胞廣泛應用於藥物代謝、肝毒性和肝功能的研究，使其成為製藥和生物技術研究的重要工具。人們日益關注如何減少藥物研發失敗並改善預測性臨床前試驗模型，這進一步推動了市場擴張。預計2026年，原代肝細胞市場規模將達2,746億美元，2033年將達4,295億美元，預測期間內年複合成長率（CAGR）為6.60%。

市場洞察：

隨著3D肝細胞培養系統、冷凍保存的肝細胞和先進的體外肝臟模型日益普及，肝細胞產業正經歷快速發展。製藥和生物技術公司越來越依賴原代肝細胞進行精準的藥物代謝和毒性評估。細胞分離、儲存和培養技術的創新提高了細胞的活力和功能，從而獲得了更可靠的研究結果。此外，基於肝細胞的檢測方法在個人化醫療和再生醫學研究中的日益廣泛應用也推動了市場成長。

促進因素：

原代肝細胞市場成長的主要促進因素包括藥物研發投入的增加、肝病發生率的上升以及對預測毒理學研究日益成長的關注。製藥和生物製藥行業的蓬勃發展推動了對可靠肝細胞模型的需求，以提高臨床前試驗的效率。監管機構也建議使用先進的體外模型來減少動物試驗，這進一步促進了原代肝細胞的應用。此外，幹細胞生物學和再生醫學領域研究活動的活性化也為市場創造了更多成長機會。

商業機會：

對於開發高品質冷凍保存肝細胞、3D球狀體模型和專用檢測平台的公司而言，該市場蘊藏著巨大的商機。新興經濟體憑藉其不斷完善的研究基礎設施和日益成長的生物技術投資，展現出極具吸引力的市場擴張潛力。學術機構、受託研究機構和生物技術公司之間的合作有望加速基於肝細胞的應用領域的創新。此外，生物工程和晶片器官技術的進步也可能在未來幾年為市場參與企業創造新的機會。

區域分析：

北美憑藉其活躍的藥物研發活動、先進的生物技術基礎設施以及對藥物發現項目的大量投資，在原代肝細胞市場佔據主導地位。主要市場參與者的存在以及先進細胞培養技術的日益普及，進一步推動了該地區的成長。歐洲由於研究經費的增加和對替代檢測方法的日益關注，佔據了相當大的市場佔有率。亞太地區預計將在預測期內實現最快成長，這主要得益於生物技術產業的擴張、臨床研究活動的增加以及中國、印度和日本等國家醫療保健投資的不斷成長。拉丁美洲以及中東和非洲地區由於研究能力的提升和對先進細胞檢測方法的日益重視，正逐漸成為極具潛力的市場。

主要公司：

  • Thermo Fisher Scientific Inc.
  • Corning Inc.
  • Lonza
  • Takara Bio Inc.
  • Cell Biologics, Inc.
  • Merck KGaA
  • American Type Culture Collection (ATCC)
  • Creative Bioarray
  • Axol Bioscience Ltd.
  • HiMedia Laboratories

分割：

副產品

  • 冷凍保存的懸浮肝細胞
  • 活懸浮液肝細胞
  • 3D（球狀）肝細胞
  • 增殖的肝細胞（適用於平板培養）
  • 未鑑定的肝細胞

類型

  • 人類
  • 鼠
  • 老鼠
  • 狗
  • 猴
  • 馬
  • 其他

透過應用和分析

  • 細胞活力檢測
  • 細胞色素酶活性
  • 高通量細胞毒性檢測
  • 轉運體抑制試驗
  • 體外內源性清除
  • 磷脂測定
  • 其他

最終用戶

  • 生物製藥公司
  • 學術和研究機構
  • 受託研究機構

按地區

  • 北美洲
  • 北美洲
  • 亞太地區
  • 拉丁美洲
  • 中東和非洲

目錄

第1章執行摘要

第2章 市場概覽

  • 市場定義與細分
  • 市場動態
    • 促進因素
    • 抑制因子
    • 市場機遇
  • 價值鏈分析
  • 新冠疫情影響分析
  • 波特五力分析
  • 俄烏衝突的影響
  • PESTLE分析
  • 監管分析
  • 價格趨勢分析
    • 當前價格及未來預測（2025-2033）
    • 價格影響因素

第3章：2020-2033年全球原代肝細胞市場展望

  • 全球原代肝細胞市場展望，按產品類型分類，價值（十億美元），2020-2033年
    • 冷凍保存的懸浮肝細胞
    • 新鮮懸浮肝細胞
    • 3D（球形）肝細胞
    • 可培養增生的肝細胞
    • 未分類的肝細胞
  • 全球原代肝細胞市場展望（按類型和價值（十億美元）分類），2020-2033年
    • 人類
    • 鼠
    • 老鼠
    • 狗
    • 猴
    • 馬
    • 其他
  • 全球原代肝細胞市場展望，按應用/測試分類，市場規模（十億美元），2020-2033年
    • 細胞活力檢測
    • 細胞色素酶活性
    • 高含量細胞毒性
    • 轉運體抑制試驗
    • 體外固有清除率
    • 磷脂測定
    • 其他
  • 全球原代肝細胞市場展望（按最終用戶分類，價值單位：十億美元），2020-2033年
    • 生物製藥公司
    • 學術和研究機構
    • 受託研究機構
  • 全球原代肝細胞市場展望（按地區和價值計，單位：十億美元），2020-2033年
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第4章：2020-2033年北美原代肝細胞市場展望

第5章：2020-2033年歐洲原代肝細胞市場展望

第6章：2020-2033年亞太地區原代肝細胞市場展望

第7章：2020-2033年拉丁美洲原代肝細胞市場展望

第8章：2020-2033年中東和非洲原代肝細胞市場展望

第9章 競爭情勢

  • 公司與細分市場熱圖
  • 2025年各公司市佔率分析
  • 競爭對手儀錶板
  • 公司簡介
    • Thermo Fisher Scientific Inc.
    • Corning Inc.
    • Lonza
    • Takara Bio Inc.
    • Cell Biologics, Inc.
    • Merck KGaA
    • American Type Culture Collection (ATCC)
    • Creative Bioarray
    • Axol Bioscience Ltd.
    • HiMedia Laboratories

第10章附錄

簡介目錄

The primary hepatocytes market is witnessing significant growth due to increasing demand for advanced cell-based research models in drug discovery, toxicology testing, and liver disease research. Primary hepatocytes are widely utilized for studying drug metabolism, hepatotoxicity, and liver function, making them essential tools in pharmaceutical and biotechnology research. Growing emphasis on reducing drug development failures and improving predictive preclinical testing models is further supporting market expansion. The Primary Hepatocytes Market is expected to reach US$ 274.6 Bn in 2026 and US$ 429.5 Bn by 2033, growing at a CAGR of 6.60% during the forecast period.

Market Insights:

The industry is experiencing rapid advancement with the increasing adoption of 3D hepatocyte culture systems, cryopreserved hepatocytes, and advanced in vitro liver models. Pharmaceutical and biotechnology companies are increasingly relying on primary hepatocytes for accurate drug metabolism and toxicity assessments. Technological innovations in cell isolation, preservation, and culture techniques are enhancing cell viability and functionality, enabling more reliable research outcomes. Additionally, the growing use of hepatocyte-based assays in personalized medicine and regenerative medicine research is contributing to market growth.

Drivers:

Key drivers of the primary hepatocytes market include rising investment in drug discovery and development, increasing prevalence of liver diseases, and growing focus on predictive toxicology studies. The expanding pharmaceutical and biopharmaceutical industries are driving demand for reliable liver cell models to improve the efficiency of preclinical testing. Regulatory agencies are also encouraging the use of advanced in vitro models to reduce animal testing, further boosting adoption of primary hepatocytes. Moreover, increasing research activities in stem cell biology and regenerative medicine are creating additional growth opportunities for the market.

Business Opportunity:

The market presents substantial business opportunities for companies developing high-quality cryopreserved hepatocytes, 3D spheroid models, and specialized assay platforms. Emerging economies are offering attractive expansion potential due to increasing research infrastructure development and growing investment in biotechnology sectors. Collaborations between academic institutions, contract research organizations, and biotechnology firms are expected to accelerate innovation in hepatocyte-based applications. Furthermore, advancements in bioengineering and organ-on-chip technologies are likely to create new opportunities for market participants in the coming years.

Region Analysis:

North America dominates the primary hepatocytes market owing to strong pharmaceutical research activities, advanced biotechnology infrastructure, and significant investment in drug discovery programs. The presence of major market players and increasing adoption of advanced cell culture technologies further support regional growth. Europe holds a substantial market share due to rising research funding and increasing focus on alternative testing methods. Asia Pacific is anticipated to witness the fastest growth during the forecast period driven by expanding biotechnology industries, increasing clinical research activities, and rising healthcare investments in countries such as China, India, and Japan. Latin America and the Middle East & Africa are gradually emerging as promising markets due to improving research capabilities and growing awareness regarding advanced cell-based assays.

Key Players:

  • Thermo Fisher Scientific Inc.
  • Corning Inc.
  • Lonza
  • Takara Bio Inc.
  • Cell Biologics, Inc.
  • Merck KGaA
  • American Type Culture Collection (ATCC)
  • Creative Bioarray
  • Axol Bioscience Ltd.
  • HiMedia Laboratories

Segmentation:

By Product

  • Cryopreserved Suspension Hepatocytes
  • Fresh Suspension Hepatocytes
  • 3D (Spheroid) Hepatocytes
  • Expanded Hepatocytes (Plateable)
  • Non-characterized Hepatocytes

By Species

  • Human
  • Rat
  • Mouse
  • Dog
  • Monkey
  • Horse
  • Others

By Application/Assay

  • Cell Viability Assay
  • Cytochrome Enzyme Activity
  • High Content Cytotoxicity
  • Transporter Inhibition Assay
  • In Vitro Intrinsic Clearance
  • Phospholipids Assay
  • Others

By End User

  • Biopharmaceutical companies
  • Academic and Research institutes
  • Contract Research Organizations

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • The Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Primary Hepatocytes Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2026
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Porter's Five Forces Analysis
  • 2.6. Impact of Russia-Ukraine Conflict
  • 2.7. PESTLE Analysis
  • 2.8. Regulatory Analysis
  • 2.9. Price Trend Analysis
    • 2.9.1. Current Prices and Future Projections, 2025-2033
    • 2.9.2. Price Impact Factors

3. Global Primary Hepatocytes Market Outlook, 2020 - 2033

  • 3.1. Global Primary Hepatocytes Market Outlook, by Product Type, Value (US$ Bn), 2020-2033
    • 3.1.1. Cryopreserved Suspension Hepatocytes
    • 3.1.2. Fresh Suspension Hepatocytes
    • 3.1.3. 3D (Spheroid) Hepatocytes
    • 3.1.4. Expanded Hepatocytes (Plateable)
    • 3.1.5. Non-characterized Hepatocytes
  • 3.2. Global Primary Hepatocytes Market Outlook, by Species, Value (US$ Bn), 2020-2033
    • 3.2.1. Human
    • 3.2.2. Rat
    • 3.2.3. Mouse
    • 3.2.4. Dog
    • 3.2.5. Monkey
    • 3.2.6. Horse
    • 3.2.7. Others
  • 3.3. Global Primary Hepatocytes Market Outlook, by Application/Assay, Value (US$ Bn), 2020-2033
    • 3.3.1. Cell Viability Assay
    • 3.3.2. Cytochrome Enzyme Activity
    • 3.3.3. High Content Cytotoxicity
    • 3.3.4. Transporter Inhibition Assay
    • 3.3.5. In Vitro Intrinsic Clearance
    • 3.3.6. Phospholipids Assay
    • 3.3.7. Others
  • 3.4. Global Primary Hepatocytes Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 3.4.1. Biopharmaceutical companies
    • 3.4.2. Academic and Research institutes
    • 3.4.3. Contract Research Organizations
  • 3.5. Global Primary Hepatocytes Market Outlook, by Region, Value (US$ Bn), 2020-2033
    • 3.5.1. North America
    • 3.5.2. Europe
    • 3.5.3. Asia Pacific
    • 3.5.4. Latin America
    • 3.5.5. Middle East & Africa

4. North America Primary Hepatocytes Market Outlook, 2020 - 2033

  • 4.1. North America Primary Hepatocytes Market Outlook, by Product Type, Value (US$ Bn), 2020-2033
    • 4.1.1. Cryopreserved Suspension Hepatocytes
    • 4.1.2. Fresh Suspension Hepatocytes
    • 4.1.3. 3D (Spheroid) Hepatocytes
    • 4.1.4. Expanded Hepatocytes (Plateable)
    • 4.1.5. Non-characterized Hepatocytes
  • 4.2. North America Primary Hepatocytes Market Outlook, by Species, Value (US$ Bn), 2020-2033
    • 4.2.1. Human
    • 4.2.2. Rat
    • 4.2.3. Mouse
    • 4.2.4. Dog
    • 4.2.5. Monkey
    • 4.2.6. Horse
    • 4.2.7. Others
  • 4.3. North America Primary Hepatocytes Market Outlook, by Application/Assay, Value (US$ Bn), 2020-2033
    • 4.3.1. Cell Viability Assay
    • 4.3.2. Cytochrome Enzyme Activity
    • 4.3.3. High Content Cytotoxicity
    • 4.3.4. Transporter Inhibition Assay
    • 4.3.5. In Vitro Intrinsic Clearance
    • 4.3.6. Phospholipids Assay
    • 4.3.7. Others
  • 4.4. North America Primary Hepatocytes Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 4.4.1. Biopharmaceutical companies
    • 4.4.2. Academic and Research institutes
    • 4.4.3. Contract Research Organizations
  • 4.5. North America Primary Hepatocytes Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 4.5.1. U.S. Primary Hepatocytes Market Outlook, by Product Type, 2020-2033
    • 4.5.2. U.S. Primary Hepatocytes Market Outlook, by Species, 2020-2033
    • 4.5.3. U.S. Primary Hepatocytes Market Outlook, by Application/Assay, 2020-2033
    • 4.5.4. U.S. Primary Hepatocytes Market Outlook, by End User, 2020-2033
    • 4.5.5. Canada Primary Hepatocytes Market Outlook, by Product Type, 2020-2033
    • 4.5.6. Canada Primary Hepatocytes Market Outlook, by Species, 2020-2033
    • 4.5.7. Canada Primary Hepatocytes Market Outlook, by Application/Assay, 2020-2033
    • 4.5.8. Canada Primary Hepatocytes Market Outlook, by End User, 2020-2033
  • 4.6. BPS Analysis/Market Attractiveness Analysis

5. Europe Primary Hepatocytes Market Outlook, 2020 - 2033

  • 5.1. Europe Primary Hepatocytes Market Outlook, by Product Type, Value (US$ Bn), 2020-2033
    • 5.1.1. Cryopreserved Suspension Hepatocytes
    • 5.1.2. Fresh Suspension Hepatocytes
    • 5.1.3. 3D (Spheroid) Hepatocytes
    • 5.1.4. Expanded Hepatocytes (Plateable)
    • 5.1.5. Non-characterized Hepatocytes
  • 5.2. Europe Primary Hepatocytes Market Outlook, by Species, Value (US$ Bn), 2020-2033
    • 5.2.1. Human
    • 5.2.2. Rat
    • 5.2.3. Mouse
    • 5.2.4. Dog
    • 5.2.5. Monkey
    • 5.2.6. Horse
    • 5.2.7. Others
  • 5.3. Europe Primary Hepatocytes Market Outlook, by Application/Assay, Value (US$ Bn), 2020-2033
    • 5.3.1. Cell Viability Assay
    • 5.3.2. Cytochrome Enzyme Activity
    • 5.3.3. High Content Cytotoxicity
    • 5.3.4. Transporter Inhibition Assay
    • 5.3.5. In Vitro Intrinsic Clearance
    • 5.3.6. Phospholipids Assay
    • 5.3.7. Others
  • 5.4. Europe Primary Hepatocytes Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 5.4.1. Biopharmaceutical companies
    • 5.4.2. Academic and Research institutes
    • 5.4.3. Contract Research Organizations
  • 5.5. Europe Primary Hepatocytes Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 5.5.1. Germany Primary Hepatocytes Market Outlook, by Product Type, 2020-2033
    • 5.5.2. Germany Primary Hepatocytes Market Outlook, by Species, 2020-2033
    • 5.5.3. Germany Primary Hepatocytes Market Outlook, by Application/Assay, 2020-2033
    • 5.5.4. Germany Primary Hepatocytes Market Outlook, by End User, 2020-2033
    • 5.5.5. Italy Primary Hepatocytes Market Outlook, by Product Type, 2020-2033
    • 5.5.6. Italy Primary Hepatocytes Market Outlook, by Species, 2020-2033
    • 5.5.7. Italy Primary Hepatocytes Market Outlook, by Application/Assay, 2020-2033
    • 5.5.8. Italy Primary Hepatocytes Market Outlook, by End User, 2020-2033
    • 5.5.9. France Primary Hepatocytes Market Outlook, by Product Type, 2020-2033
    • 5.5.10. France Primary Hepatocytes Market Outlook, by Species, 2020-2033
    • 5.5.11. France Primary Hepatocytes Market Outlook, by Application/Assay, 2020-2033
    • 5.5.12. France Primary Hepatocytes Market Outlook, by End User, 2020-2033
    • 5.5.13. U.K. Primary Hepatocytes Market Outlook, by Product Type, 2020-2033
    • 5.5.14. U.K. Primary Hepatocytes Market Outlook, by Species, 2020-2033
    • 5.5.15. U.K. Primary Hepatocytes Market Outlook, by Application/Assay, 2020-2033
    • 5.5.16. U.K. Primary Hepatocytes Market Outlook, by End User, 2020-2033
    • 5.5.17. Spain Primary Hepatocytes Market Outlook, by Product Type, 2020-2033
    • 5.5.18. Spain Primary Hepatocytes Market Outlook, by Species, 2020-2033
    • 5.5.19. Spain Primary Hepatocytes Market Outlook, by Application/Assay, 2020-2033
    • 5.5.20. Spain Primary Hepatocytes Market Outlook, by End User, 2020-2033
    • 5.5.21. Russia Primary Hepatocytes Market Outlook, by Product Type, 2020-2033
    • 5.5.22. Russia Primary Hepatocytes Market Outlook, by Species, 2020-2033
    • 5.5.23. Russia Primary Hepatocytes Market Outlook, by Application/Assay, 2020-2033
    • 5.5.24. Russia Primary Hepatocytes Market Outlook, by End User, 2020-2033
    • 5.5.25. Rest of Europe Primary Hepatocytes Market Outlook, by Product Type, 2020-2033
    • 5.5.26. Rest of Europe Primary Hepatocytes Market Outlook, by Species, 2020-2033
    • 5.5.27. Rest of Europe Primary Hepatocytes Market Outlook, by Application/Assay, 2020-2033
    • 5.5.28. Rest of Europe Primary Hepatocytes Market Outlook, by End User, 2020-2033
  • 5.6. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Primary Hepatocytes Market Outlook, 2020 - 2033

  • 6.1. Asia Pacific Primary Hepatocytes Market Outlook, by Product Type, Value (US$ Bn), 2020-2033
    • 6.1.1. Cryopreserved Suspension Hepatocytes
    • 6.1.2. Fresh Suspension Hepatocytes
    • 6.1.3. 3D (Spheroid) Hepatocytes
    • 6.1.4. Expanded Hepatocytes (Plateable)
    • 6.1.5. Non-characterized Hepatocytes
  • 6.2. Asia Pacific Primary Hepatocytes Market Outlook, by Species, Value (US$ Bn), 2020-2033
    • 6.2.1. Human
    • 6.2.2. Rat
    • 6.2.3. Mouse
    • 6.2.4. Dog
    • 6.2.5. Monkey
    • 6.2.6. Horse
    • 6.2.7. Others
  • 6.3. Asia Pacific Primary Hepatocytes Market Outlook, by Application/Assay, Value (US$ Bn), 2020-2033
    • 6.3.1. Cell Viability Assay
    • 6.3.2. Cytochrome Enzyme Activity
    • 6.3.3. High Content Cytotoxicity
    • 6.3.4. Transporter Inhibition Assay
    • 6.3.5. In Vitro Intrinsic Clearance
    • 6.3.6. Phospholipids Assay
    • 6.3.7. Others
  • 6.4. Asia Pacific Primary Hepatocytes Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 6.4.1. Biopharmaceutical companies
    • 6.4.2. Academic and Research institutes
    • 6.4.3. Contract Research Organizations
  • 6.5. Asia Pacific Primary Hepatocytes Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 6.5.1. China Primary Hepatocytes Market Outlook, by Product Type, 2020-2033
    • 6.5.2. China Primary Hepatocytes Market Outlook, by Species, 2020-2033
    • 6.5.3. China Primary Hepatocytes Market Outlook, by Application/Assay, 2020-2033
    • 6.5.4. China Primary Hepatocytes Market Outlook, by End User, 2020-2033
    • 6.5.5. Japan Primary Hepatocytes Market Outlook, by Product Type, 2020-2033
    • 6.5.6. Japan Primary Hepatocytes Market Outlook, by Species, 2020-2033
    • 6.5.7. Japan Primary Hepatocytes Market Outlook, by Application/Assay, 2020-2033
    • 6.5.8. Japan Primary Hepatocytes Market Outlook, by End User, 2020-2033
    • 6.5.9. South Korea Primary Hepatocytes Market Outlook, by Product Type, 2020-2033
    • 6.5.10. South Korea Primary Hepatocytes Market Outlook, by Species, 2020-2033
    • 6.5.11. South Korea Primary Hepatocytes Market Outlook, by Application/Assay, 2020-2033
    • 6.5.12. South Korea Primary Hepatocytes Market Outlook, by End User, 2020-2033
    • 6.5.13. India Primary Hepatocytes Market Outlook, by Product Type, 2020-2033
    • 6.5.14. India Primary Hepatocytes Market Outlook, by Species, 2020-2033
    • 6.5.15. India Primary Hepatocytes Market Outlook, by Application/Assay, 2020-2033
    • 6.5.16. India Primary Hepatocytes Market Outlook, by End User, 2020-2033
    • 6.5.17. Southeast Asia Primary Hepatocytes Market Outlook, by Product Type, 2020-2033
    • 6.5.18. Southeast Asia Primary Hepatocytes Market Outlook, by Species, 2020-2033
    • 6.5.19. Southeast Asia Primary Hepatocytes Market Outlook, by Application/Assay, 2020-2033
    • 6.5.20. Southeast Asia Primary Hepatocytes Market Outlook, by End User, 2020-2033
    • 6.5.21. Rest of SAO Primary Hepatocytes Market Outlook, by Product Type, 2020-2033
    • 6.5.22. Rest of SAO Primary Hepatocytes Market Outlook, by Species, 2020-2033
    • 6.5.23. Rest of SAO Primary Hepatocytes Market Outlook, by Application/Assay, 2020-2033
    • 6.5.24. Rest of SAO Primary Hepatocytes Market Outlook, by End User, 2020-2033
  • 6.6. BPS Analysis/Market Attractiveness Analysis

7. Latin America Primary Hepatocytes Market Outlook, 2020 - 2033

  • 7.1. Latin America Primary Hepatocytes Market Outlook, by Product Type, Value (US$ Bn), 2020-2033
    • 7.1.1. Cryopreserved Suspension Hepatocytes
    • 7.1.2. Fresh Suspension Hepatocytes
    • 7.1.3. 3D (Spheroid) Hepatocytes
    • 7.1.4. Expanded Hepatocytes (Plateable)
    • 7.1.5. Non-characterized Hepatocytes
  • 7.2. Latin America Primary Hepatocytes Market Outlook, by Species, Value (US$ Bn), 2020-2033
    • 7.2.1. Human
    • 7.2.2. Rat
    • 7.2.3. Mouse
    • 7.2.4. Dog
    • 7.2.5. Monkey
    • 7.2.6. Horse
    • 7.2.7. Others
  • 7.3. Latin America Primary Hepatocytes Market Outlook, by Application/Assay, Value (US$ Bn), 2020-2033
    • 7.3.1. Cell Viability Assay
    • 7.3.2. Cytochrome Enzyme Activity
    • 7.3.3. High Content Cytotoxicity
    • 7.3.4. Transporter Inhibition Assay
    • 7.3.5. In Vitro Intrinsic Clearance
    • 7.3.6. Phospholipids Assay
    • 7.3.7. Others
  • 7.4. Latin America Primary Hepatocytes Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 7.4.1. Biopharmaceutical companies
    • 7.4.2. Academic and Research institutes
    • 7.4.3. Contract Research Organizations
  • 7.5. Latin America Primary Hepatocytes Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 7.5.1. Brazil Primary Hepatocytes Market Outlook, by Product Type, 2020-2033
    • 7.5.2. Brazil Primary Hepatocytes Market Outlook, by Species, 2020-2033
    • 7.5.3. Brazil Primary Hepatocytes Market Outlook, by Application/Assay, 2020-2033
    • 7.5.4. Brazil Primary Hepatocytes Market Outlook, by End User, 2020-2033
    • 7.5.5. Mexico Primary Hepatocytes Market Outlook, by Product Type, 2020-2033
    • 7.5.6. Mexico Primary Hepatocytes Market Outlook, by Species, 2020-2033
    • 7.5.7. Mexico Primary Hepatocytes Market Outlook, by Application/Assay, 2020-2033
    • 7.5.8. Mexico Primary Hepatocytes Market Outlook, by End User, 2020-2033
    • 7.5.9. Argentina Primary Hepatocytes Market Outlook, by Product Type, 2020-2033
    • 7.5.10. Argentina Primary Hepatocytes Market Outlook, by Species, 2020-2033
    • 7.5.11. Argentina Primary Hepatocytes Market Outlook, by Application/Assay, 2020-2033
    • 7.5.12. Argentina Primary Hepatocytes Market Outlook, by End User, 2020-2033
    • 7.5.13. Rest of LATAM Primary Hepatocytes Market Outlook, by Product Type, 2020-2033
    • 7.5.14. Rest of LATAM Primary Hepatocytes Market Outlook, by Species, 2020-2033
    • 7.5.15. Rest of LATAM Primary Hepatocytes Market Outlook, by Application/Assay, 2020-2033
    • 7.5.16. Rest of LATAM Primary Hepatocytes Market Outlook, by End User, 2020-2033
  • 7.6. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Primary Hepatocytes Market Outlook, 2020 - 2033

  • 8.1. Middle East & Africa Primary Hepatocytes Market Outlook, by Product Type, Value (US$ Bn), 2020-2033
    • 8.1.1. Cryopreserved Suspension Hepatocytes
    • 8.1.2. Fresh Suspension Hepatocytes
    • 8.1.3. 3D (Spheroid) Hepatocytes
    • 8.1.4. Expanded Hepatocytes (Plateable)
    • 8.1.5. Non-characterized Hepatocytes
  • 8.2. Middle East & Africa Primary Hepatocytes Market Outlook, by Species, Value (US$ Bn), 2020-2033
    • 8.2.1. Human
    • 8.2.2. Rat
    • 8.2.3. Mouse
    • 8.2.4. Dog
    • 8.2.5. Monkey
    • 8.2.6. Horse
    • 8.2.7. Others
  • 8.3. Middle East & Africa Primary Hepatocytes Market Outlook, by Application/Assay, Value (US$ Bn), 2020-2033
    • 8.3.1. Cell Viability Assay
    • 8.3.2. Cytochrome Enzyme Activity
    • 8.3.3. High Content Cytotoxicity
    • 8.3.4. Transporter Inhibition Assay
    • 8.3.5. In Vitro Intrinsic Clearance
    • 8.3.6. Phospholipids Assay
    • 8.3.7. Others
  • 8.4. Middle East & Africa Primary Hepatocytes Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 8.4.1. Biopharmaceutical companies
    • 8.4.2. Academic and Research institutes
    • 8.4.3. Contract Research Organizations
  • 8.5. Middle East & Africa Primary Hepatocytes Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 8.5.1. GCC Primary Hepatocytes Market Outlook, by Product Type, 2020-2033
    • 8.5.2. GCC Primary Hepatocytes Market Outlook, by Species, 2020-2033
    • 8.5.3. GCC Primary Hepatocytes Market Outlook, by Application/Assay, 2020-2033
    • 8.5.4. GCC Primary Hepatocytes Market Outlook, by End User, 2020-2033
    • 8.5.5. South Africa Primary Hepatocytes Market Outlook, by Product Type, 2020-2033
    • 8.5.6. South Africa Primary Hepatocytes Market Outlook, by Species, 2020-2033
    • 8.5.7. South Africa Primary Hepatocytes Market Outlook, by Application/Assay, 2020-2033
    • 8.5.8. South Africa Primary Hepatocytes Market Outlook, by End User, 2020-2033
    • 8.5.9. Egypt Primary Hepatocytes Market Outlook, by Product Type, 2020-2033
    • 8.5.10. Egypt Primary Hepatocytes Market Outlook, by Species, 2020-2033
    • 8.5.11. Egypt Primary Hepatocytes Market Outlook, by Application/Assay, 2020-2033
    • 8.5.12. Egypt Primary Hepatocytes Market Outlook, by End User, 2020-2033
    • 8.5.13. Nigeria Primary Hepatocytes Market Outlook, by Product Type, 2020-2033
    • 8.5.14. Nigeria Primary Hepatocytes Market Outlook, by Species, 2020-2033
    • 8.5.15. Nigeria Primary Hepatocytes Market Outlook, by Application/Assay, 2020-2033
    • 8.5.16. Nigeria Primary Hepatocytes Market Outlook, by End User, 2020-2033
    • 8.5.17. Rest of Middle East Primary Hepatocytes Market Outlook, by Product Type, 2020-2033
    • 8.5.18. Rest of Middle East Primary Hepatocytes Market Outlook, by Species, 2020-2033
    • 8.5.19. Rest of Middle East Primary Hepatocytes Market Outlook, by Application/Assay, 2020-2033
    • 8.5.20. Rest of Middle East Primary Hepatocytes Market Outlook, by End User, 2020-2033
  • 8.6. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Company Vs Segment Heatmap
  • 9.2. Company Market Share Analysis, 2025
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. Thermo Fisher Scientific Inc.
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Product Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Developments
    • 9.4.2. Corning Inc.
    • 9.4.3. Lonza
    • 9.4.4. Takara Bio Inc.
    • 9.4.5. Cell Biologics, Inc.
    • 9.4.6. Merck KGaA
    • 9.4.7. American Type Culture Collection (ATCC)
    • 9.4.8. Creative Bioarray
    • 9.4.9. Axol Bioscience Ltd.
    • 9.4.10. HiMedia Laboratories

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations